MedTrace Logo

FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole

NCT00199134 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2015-01-06

No results posted yet for this study

Summary

Find a genetic signature of de novo resistance to letrozole in adjuvant breast cancer;

Conditions

Interventions

DRUG

Letrozole

Size of the tumor is followed

Sponsors & Collaborators

  • Feculdade de Medicina da Universidade de Sao Paulo - Brasil

    collaborator OTHER

  • Hospital de Clinicas de Porto Alegre

    collaborator OTHER

  • Hospital do Cancer, Sao Paulo

    collaborator OTHER

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Christos Sotiriou, MD, PhD · Jules Bordet Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199134 on ClinicalTrials.gov